Key Highlights

  • Provexis plc (LSE:PXS) rose 1.50% on the AIM market of the London Stock Exchange on 20 October 2026.
  • Record half-year sales of more than £900,000 were achieved in the six months to 31 March 2026.
  • Full-year revenue was £1.26 million, broadly in line with £1.29 million a year earlier.
  • Cash increased to £893,000 at 31 March 2026 from £708,000.
  • Royalty payments to dsm-firmenich are due to cease entirely on 31 December 2026, improving future margins.

Why Provexis (LSE:PXS) Is in Focus Today

Provexis plc, which develops, licenses and sells the scientifically proven Fruitflow heart-health functional food ingredient, gained 1.50% on the AIM market on 20 October 2026. The move follows preliminary results released on 30 September 2026 that highlighted record half-year sales, and LSE:PXS remains a favourite among retail investors seeking small-cap exposure to the nutrition and supplements market.

What Is Fruitflow?

Fruitflow is a natural extract from tomatoes that has been shown in human trials to reduce the propensity for aberrant blood clotting, which is associated with cardiovascular disease, heart attack and stroke. It is available as a spray-dried powder that can be included in food, beverage and supplement formats. Provexis sells Fruitflow II SD as an ingredient to brand owners and also offers Fruitflow+ Omega-3 to consumers.

FY26 Results: A Record Second Half

For the year ended 31 March 2026, total revenue was £1.26 million compared with £1.29 million. Fruitflow II SD contributed £1.15 million and Fruitflow+ Omega-3 £116,000. The headline was a record second half, with sales of more than £900,000 in the six months to 31 March 2026, a sharp recovery from a first half hit by a late production run.

Cash rose to £893,000 at the year end from £708,000, showing improved working capital management.

Supply Chain and EU Operations

Fruitflow II SD is manufactured in the EU. To serve European customers efficiently after Brexit, Provexis set up Provexis Ireland Limited, which began selling to EU customers in April 2024 via an outsourced fulfilment centre. The company planned at least three production runs during 2026 to meet demand from existing and new customers.

Partners: dsm-firmenich and Byhealth

Provexis previously worked with DSM, now dsm-firmenich, which distributed Fruitflow globally. Under revised agreements, Provexis now sells directly to former DSM customers and new customers. Importantly, the royalty payable on these sales has been decreasing and will cease completely on 31 December 2026, which should boost Provexis' margins from 2027.

In China, the planned launch of Fruitflow products by dietary supplement company Byhealth has been progressing, representing a potentially significant market.

Risks Investors Are Weighing

Provexis is a very small company, so a single production delay can materially affect results, as happened in 2025. Revenue depends on a limited number of customers, and cash resources are modest. The shares trade at a low price and can be highly volatile.

The Functional Food and Supplement Opportunity

Consumers are increasingly interested in foods and supplements that support specific health outcomes, and heart health is one of the largest categories. Fruitflow's appeal lies in its natural origin, scientific evidence base and approved health claims in key markets. It can be incorporated into supplements, drinks and food products, giving brand owners flexibility in how they use it.

Provexis has also investigated other potential benefits. A human study supported the use of Fruitflow for modulating gut microbiota, including a reduction in TMAO, a compound associated with cardiovascular risk. Such findings can open new marketing opportunities for customers.

The end of royalty payments at the end of 2026 is a structural improvement for Provexis plc. As more revenue flows directly to the company, operating leverage could improve meaningfully, provided sales volumes keep growing. For LSE:PXS, the combination of record sales, improving margins and new market launches underpins investor interest.

What Investors Are Watching Next

Investors in Provexis plc will look for interim results for the six months to 30 September 2026, typically released in December, to judge whether sales momentum has continued. Further production runs, new customer wins, the Byhealth launch in China and the end of the royalty in December 2026 are key catalysts. The annual general meeting will also provide an opportunity for a trading update.

The 1.50% rise on 20 October 2026 indicates that investors are beginning to price in a stronger trading profile. Consistent production runs, a growing customer list and the margin benefit from the end of royalty payments will determine whether that momentum can be sustained into 2027.